<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935752</url>
  </required_header>
  <id_info>
    <org_study_id>P110301</org_study_id>
    <nct_id>NCT01935752</nct_id>
  </id_info>
  <brief_title>Pathophysiological Mechanisms of Fibromuscular Dysplasia</brief_title>
  <acronym>MeDyA</acronym>
  <official_title>Pathophysiological Mechanisms of Fibromuscular Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation pour la Recherche Médicale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromuscular dysplasia is an non inflammatory non atherosclerotic obstructive arterial
      disease affecting mid-size arteries. It is considered as a rare vascular disease of unknown
      origin. Fibromuscular dysplasia may become symptomatic depending on location and severity of
      narrowing of the arterial lumen. for example,when a stenosis develops within a renal artery,
      arterial hypertension may develop. The cause of fibromuscular dysplasia is unknown. Several
      factors have been suggested to be associated with it: tobacco abuse or oestrogens. In order
      to progress into identifying possible causative mechanisms of the disease, we design a
      pathophysiology study destined to assess endothelial function in patients with fibromuscular
      dysplasia and to identify possible plasmatic biomarkers of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of circulating microparticles of patients vs. fibromuscular dysplasia with age and sex matched healthy volunteers and hypertensive patients</measure>
    <time_frame>Once within 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of circulating micro RNAs (miR-143 ; miR-145) between the 3 arms</measure>
    <time_frame>Once within 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of matrixmetalloproteases between the 3 arms</measure>
    <time_frame>Once within 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of c-reactive protein between the 3 arms</measure>
    <time_frame>Once within 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of PLA2 between the 3 arms</measure>
    <time_frame>Once within 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of endothelium dependant vasodilation between the 3 arms</measure>
    <time_frame>Once within 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of endothelium independent vasodilation between the 3 arms</measure>
    <time_frame>Once within 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pulse wave velocity between the 3 arms</measure>
    <time_frame>Once within 15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Fibromuscular Dysplasia</condition>
  <arm_group>
    <arm_group_label>Fibromuscular dysplasia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fibromuscular dysplasia:blood samples &amp; vascular echotracking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy volunteer:blood samples &amp; vascular echotracking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertensive patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>hypertensive patients:blood samples &amp; vascular echotracking</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>blood samples</description>
    <arm_group_label>Fibromuscular dysplasia</arm_group_label>
    <arm_group_label>healthy volunteer</arm_group_label>
    <arm_group_label>hypertensive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>vascular echotracking</intervention_name>
    <description>endothelial function study and virtual histology study</description>
    <arm_group_label>Fibromuscular dysplasia</arm_group_label>
    <arm_group_label>healthy volunteer</arm_group_label>
    <arm_group_label>hypertensive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients with multifocal fibromuscular dysplasia:

          -  confirmed multifocal fibromuscular dysplasia

          -  diagnosed for less than 10 years

          -  without significant atherosclerotic disease or recent cardiovascular event

          -  Statins and antiplatelet drugs are forbidden

          -  hypertensive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Azizi, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HEGP, APHP, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cic9201, Hegp, Aphp,</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2013</study_first_submitted>
  <study_first_submitted_qc>September 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibromuscular</keyword>
  <keyword>dysplasia</keyword>
  <keyword>endothelium</keyword>
  <keyword>microparticles</keyword>
  <keyword>microRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Fibromuscular Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

